Blancher M, Maignan M, Clapé C, et al. - Through a prospective, randomized, multicenter non-inferiority trial conducted in the emergency departments of 6 hospitals across France, researchers discovered whether intranasal (IN) sufentanil (INS) for individuals presenting to an emergency department with acute severe traumatic pain lead to a decrease in pain intensity non-inferior to intravenous morphine (IVM, most prevalent strong analgesic used in trauma, although it is correlated with a clear time limitation linked to the requirement to obtain an access route). As the lower 97.5% confidence interval of 0.29 was above the prespecified margin of −1.3, non-inferiority was exhibited. INS was superior to IVM, however, without a clinically important variation in mean numerical pain rating among groups. Six and two severe adverse events were noted in the INS group and in the IVM group, respectively, including an apparent imbalance for hypoxemia and for bradypnea. Therefore, for pain decrease at 30 minutes following administration in patients with severe traumatic pain presenting to an emergency department, the non-inferiority of INS in comparison with IVM was validated. The IN route, with no requirement to get a venous route, may allow early and efficient analgesia in emergency settings and in stressful situations. Moreover, verification of the safety profile of INS would need further larger studies.